Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
| This article is part of MPR‘s coverage of CHEST 2018 meeting, taking place in San Antonio, TX. Our on-site staff will be reporting on the latest breaking research and clinical advances in infectious diseases. Check back regularly for highlights from CHEST 2018 meeting. |
SAN ANTONIO — People with acute respiratory distress syndrome (ARDS) and a confirmed influenza diagnosis treated ≤6 hours with oseltamivir had reduced length of hospital stay and a lower mortality rate, according to the results of a study presented at the CHEST Annual Meeting, held from October 6 through October 10, in San Antonio, Texas.
This multicenter retrospective study examined demographic data, laboratory results, ventilator parameters, comorbidities, disease severity, mortality, and length of hospital stay in patients with influenza and ARDS (n=282; median age, 60 years). Comparisons were made between patients who received oseltamivir <6 hours from triage and those who received oseltamivir >6 hours from triage.
Overall 30- and 60-day mortalities were 23% and 31%, respectively. Compared with 9.9% of patients who received oseltamivir >6 hours, those who received the drug within 6 hours had a lower 60-day mortality rate. Early oseltamivir administration was associated with shortened length of hospital stay across all intervals. However, time to first oseltamivir administration was not linked to any differences in ventilator days, intensive care unit length of stay, or neurologic or cardiovascular complications.
Researchers noted that reducing the lengths of hospital stay may prevent hospital-acquired infections and the associated complications, which may lead to lower mortality. “Early antivirus agent use may be encouraged despite an unestablished diagnosis of influenza infection in ARDS patients,” they concluded.
|
Visit MPR‘s conference section for continuous coverage from CHEST 2018. |
Reference
Ju T, Chen W, Lee C, Liang S-J. Golden hour for administering oseltamivir in severe influenza complicating ARDS? A multicenter retrospective study. Presented at: CHEST Annual Meeting 2018; October 6-10, 2018; San Antonio, TX.
This article originally appeared on Pulmonology Advisor
